Report cover image

Anti-PCSK9 Monoclonal Antibody Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 105 Pages
SKU # APRC20353202

Description

Summary

According to APO Research, the global Anti-PCSK9 Monoclonal Antibody market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Anti-PCSK9 Monoclonal Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Anti-PCSK9 Monoclonal Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Anti-PCSK9 Monoclonal Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Anti-PCSK9 Monoclonal Antibody include Sanofi + Regeneron and Amgen etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Anti-PCSK9 Monoclonal Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-PCSK9 Monoclonal Antibody.

The report will help the Anti-PCSK9 Monoclonal Antibody manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Anti-PCSK9 Monoclonal Antibody market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anti-PCSK9 Monoclonal Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Anti-PCSK9 Monoclonal Antibody Segment by Company

Sanofi + Regeneron
Amgen
Anti-PCSK9 Monoclonal Antibody Segment by Type

Alizumab
Evolocumab
Anti-PCSK9 Monoclonal Antibody Segment by Application

Hypercholesterolemia
Atherosclerotic Cardiovascular Disease
Others
Anti-PCSK9 Monoclonal Antibody Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-PCSK9 Monoclonal Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-PCSK9 Monoclonal Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-PCSK9 Monoclonal Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anti-PCSK9 Monoclonal Antibody manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anti-PCSK9 Monoclonal Antibody by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anti-PCSK9 Monoclonal Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

105 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Anti-PCSK9 Monoclonal Antibody Market Size (2020-2031)
2.2.2 Global Anti-PCSK9 Monoclonal Antibody Sales (2020-2031)
2.2.3 Global Anti-PCSK9 Monoclonal Antibody Market Average Price (2020-2031)
2.3 Anti-PCSK9 Monoclonal Antibody by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Alizumab
2.3.3 Evolocumab
2.4 Anti-PCSK9 Monoclonal Antibody by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hypercholesterolemia
2.4.3 Atherosclerotic Cardiovascular Disease
2.4.4 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Anti-PCSK9 Monoclonal Antibody Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Anti-PCSK9 Monoclonal Antibody Sales (Kg) of Manufacturers (2020-2025)
3.3 Global Anti-PCSK9 Monoclonal Antibody Revenue of Manufacturers (2020-2025)
3.4 Global Anti-PCSK9 Monoclonal Antibody Average Price by Manufacturers (2020-2025)
3.5 Global Anti-PCSK9 Monoclonal Antibody Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Anti-PCSK9 Monoclonal Antibody, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Anti-PCSK9 Monoclonal Antibody, Product Type & Application
3.8 Global Manufacturers of Anti-PCSK9 Monoclonal Antibody, Established Date
3.9 Global Anti-PCSK9 Monoclonal Antibody Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Sanofi + Regeneron
4.1.1 Sanofi + Regeneron Company Information
4.1.2 Sanofi + Regeneron Business Overview
4.1.3 Sanofi + Regeneron Anti-PCSK9 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Sanofi + Regeneron Anti-PCSK9 Monoclonal Antibody Product Portfolio
4.1.5 Sanofi + Regeneron Recent Developments
4.2 Amgen
4.2.1 Amgen Company Information
4.2.2 Amgen Business Overview
4.2.3 Amgen Anti-PCSK9 Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Amgen Anti-PCSK9 Monoclonal Antibody Product Portfolio
4.2.5 Amgen Recent Developments
5 Global Anti-PCSK9 Monoclonal Antibody Market Scenario by Region
5.1 Global Anti-PCSK9 Monoclonal Antibody Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Anti-PCSK9 Monoclonal Antibody Sales by Region: 2020-2031
5.2.1 Global Anti-PCSK9 Monoclonal Antibody Sales by Region: 2020-2025
5.2.2 Global Anti-PCSK9 Monoclonal Antibody Sales by Region: 2026-2031
5.3 Global Anti-PCSK9 Monoclonal Antibody Revenue by Region: 2020-2031
5.3.1 Global Anti-PCSK9 Monoclonal Antibody Revenue by Region: 2020-2025
5.3.2 Global Anti-PCSK9 Monoclonal Antibody Revenue by Region: 2026-2031
5.4 North America Anti-PCSK9 Monoclonal Antibody Market Facts & Figures by Country
5.4.1 North America Anti-PCSK9 Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Anti-PCSK9 Monoclonal Antibody Sales by Country (2020-2031)
5.4.3 North America Anti-PCSK9 Monoclonal Antibody Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Anti-PCSK9 Monoclonal Antibody Market Facts & Figures by Country
5.5.1 Europe Anti-PCSK9 Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Anti-PCSK9 Monoclonal Antibody Sales by Country (2020-2031)
5.5.3 Europe Anti-PCSK9 Monoclonal Antibody Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Anti-PCSK9 Monoclonal Antibody Market Facts & Figures by Country
5.6.1 Asia Pacific Anti-PCSK9 Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Anti-PCSK9 Monoclonal Antibody Sales by Country (2020-2031)
5.6.3 Asia Pacific Anti-PCSK9 Monoclonal Antibody Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Anti-PCSK9 Monoclonal Antibody Market Facts & Figures by Country
5.7.1 South America Anti-PCSK9 Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Anti-PCSK9 Monoclonal Antibody Sales by Country (2020-2031)
5.7.3 South America Anti-PCSK9 Monoclonal Antibody Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.7.7 Colombia
5.8 Middle East and Africa Anti-PCSK9 Monoclonal Antibody Market Facts & Figures by Country
5.8.1 Middle East and Africa Anti-PCSK9 Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Anti-PCSK9 Monoclonal Antibody Sales by Country (2020-2031)
5.8.3 Middle East and Africa Anti-PCSK9 Monoclonal Antibody Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Anti-PCSK9 Monoclonal Antibody Sales by Type (2020-2031)
6.1.1 Global Anti-PCSK9 Monoclonal Antibody Sales by Type (2020-2031) & (Kg)
6.1.2 Global Anti-PCSK9 Monoclonal Antibody Sales Market Share by Type (2020-2031)
6.2 Global Anti-PCSK9 Monoclonal Antibody Revenue by Type (2020-2031)
6.2.1 Global Anti-PCSK9 Monoclonal Antibody Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Anti-PCSK9 Monoclonal Antibody Revenue Market Share by Type (2020-2031)
6.3 Global Anti-PCSK9 Monoclonal Antibody Price by Type (2020-2031)
7 Segment by Application
7.1 Global Anti-PCSK9 Monoclonal Antibody Sales by Application (2020-2031)
7.1.1 Global Anti-PCSK9 Monoclonal Antibody Sales by Application (2020-2031) & (Kg)
7.1.2 Global Anti-PCSK9 Monoclonal Antibody Sales Market Share by Application (2020-2031)
7.2 Global Anti-PCSK9 Monoclonal Antibody Revenue by Application (2020-2031)
7.2.1 Global Anti-PCSK9 Monoclonal Antibody Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Anti-PCSK9 Monoclonal Antibody Revenue Market Share by Application (2020-2031)
7.3 Global Anti-PCSK9 Monoclonal Antibody Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Anti-PCSK9 Monoclonal Antibody Value Chain Analysis
8.1.1 Anti-PCSK9 Monoclonal Antibody Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Anti-PCSK9 Monoclonal Antibody Production Mode & Process
8.2 Anti-PCSK9 Monoclonal Antibody Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Anti-PCSK9 Monoclonal Antibody Distributors
8.2.3 Anti-PCSK9 Monoclonal Antibody Customers
9 Global Anti-PCSK9 Monoclonal Antibody Analyzing Market Dynamics
9.1 Anti-PCSK9 Monoclonal Antibody Industry Trends
9.2 Anti-PCSK9 Monoclonal Antibody Industry Drivers
9.3 Anti-PCSK9 Monoclonal Antibody Industry Opportunities and Challenges
9.4 Anti-PCSK9 Monoclonal Antibody Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.